Medical Biochemistry Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
General Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Biotechnol Appl Biochem. 2021 Aug;68(4):732-743. doi: 10.1002/bab.1986. Epub 2020 Jul 24.
Circulating miRNAs gathered much interest in cancer research as noninvasive biomarkers. The aim of this study was to analyze the expression of miR-29c and miR-149 among colorectal cancer (CRC) patients and to explore their diagnostic and prognostic potentials in relation to the clinical and pathological features. The expression levels of miR-29c and miR-149 were evaluated in the sera of 80 CRC patients, 80 colorectal adenoma (CRA) patients, and 80 healthy controls using quantitative real time polymerase chain reaction (PCR). Carcinoembryonic antigen serum levels were assayed using enzyme-linked immunosorbent assay. miR-29c and miR-149 were significantly downregulated among CRC patients compared with CRA and controls (miR-29c, 0.54 ± 0.19 vs. 0.86 ± 0.12, 0.99 ± 0.07, P < 0.001, respectively; miR-149, 0.46 ± 0.19 vs. 0.74 ± 0.012, 1.0 ± 0.22, P < 0.001, respectively). miR-29c and miR-149 significantly associated with advanced stages of CRC, tumor size, and lymphatic metastasis. By using receiver operating characteristic curve analysis, combined miR-29c and miR-149 revealed the highest diagnostic potential for CRA (area under the curve [AUC] = 0.967) from healthy controls as well as the diagnosis of CRC (AUC = 0.98) from CRA. Moreover, combined miRNAs revealed high diagnostic potential for the earlier stages of CRC compared with advanced stages (AUC = 0.96). In conclusion, combined serum miR-29c and miR-149 expression analysis established novel noninvasive biomarker for early CRC diagnosis.
循环 miRNA 在癌症研究中作为非侵入性生物标志物受到广泛关注。本研究旨在分析结直肠癌（CRC）患者中 miR-29c 和 miR-149 的表达，并探讨其与临床病理特征的诊断和预后潜力。采用实时定量聚合酶链反应（PCR）检测 80 例 CRC 患者、80 例结直肠腺瘤（CRA）患者和 80 例健康对照者血清中 miR-29c 和 miR-149 的表达水平。采用酶联免疫吸附试验检测癌胚抗原血清水平。与 CRA 和对照组相比，CRC 患者的 miR-29c 和 miR-149 表达显著下调（miR-29c，0.54±0.19 比 0.86±0.12，0.99±0.07，P<0.001；miR-149，0.46±0.19 比 0.74±0.012，1.0±0.22，P<0.001）。miR-29c 和 miR-149 与 CRC 的晚期分期、肿瘤大小和淋巴转移显著相关。通过受试者工作特征曲线分析，联合 miR-29c 和 miR-149 对 CRA（曲线下面积[AUC]为 0.967）和 CRC（AUC 为 0.98）从健康对照组的诊断具有最高的诊断潜力。此外，联合 miRNA 对 CRC 早期分期的诊断潜力高于晚期分期（AUC 为 0.96）。总之，联合检测血清 miR-29c 和 miR-149 的表达分析建立了一种新的用于早期 CRC 诊断的非侵入性生物标志物。
